Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan

Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan 600 mg/200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 25–26

HOS-225173 · Präparat HOS-217408

25  Effects on medicinal product levels Recommendation concerning co- administration with Mean percent change in AUC, Medicinal product by therapeutic efavirenz/emtricitabine/tenofovir Cmax, Cmin with 90% areas disoproxil (efavirenz 600 mg, confidence intervals if emtricitabine 200 mg, tenofovir available disoproxil 245 mg) (mechanism) Selective serotonin reuptake inhibitors (SSRIs) Sertraline/Efavirenz Sertraline: When co-administered with (50 mg q.d./600 mg q.d.) AUC: ↓ 39% (↓ 27 to ↓ 50) efavirenz/emtricitabine/tenofovir Cmax: ↓ 29% (↓ 15 to ↓ 40) disoproxil, sertraline dose increases Cmin: ↓ 46% (↓ 31 to ↓ 58) should be guided by clinical Efavirenz: response. AUC: ↔ Cmax: ↑ 11% (↑ 6 to ↑ 16) Cmin: ↔ (CYP3A4 induction) Sertraline/Emtricitabine Interaction not studied. Sertraline/Tenofovir disoproxil Interaction not studied. Paroxetine/Efavirenz Paroxetine: Efavirenz/emtricitabine/tenofovir (20 mg q.d./600 mg q.d.) AUC: ↔ disoproxil and paroxetine can be co- Cmax: ↔ administered without dose Cmin: ↔ adjustment. Efavirenz: AUC: ↔ Cmax: ↔ Cmin: ↔ Paroxetine/Emtricitabine Interaction not studied. Paroxetine/Tenofovir disoproxil Interaction not studied. Fluoxetine/Efavirenz Interaction not studied. Since Efavirenz/emtricitabine/tenofovir fluoxetine shares a similar disoproxil and fluoxetine can be co- metabolic profile with administered without dose paroxetine, i.e. a strong CYP2D6 adjustment. inhibitory effect, a similar lack of interaction would be expected for fluoxetine. Fluoxetine/Emtricitabine Interaction not studied. Fluoxetine/Tenofovir disoproxil Interaction not studied. Norepinephrine and dopamine reuptake inhibitor Bupropion/Efavirenz Bupropion: Increases in bupropion dose should [150 mg single dose (sustained AUC: ↓ 55% (↓ 48 to ↓ 62) be guided by clinical response, but release)/600 mg q.d.] Cmax: ↓ 34% (↓ 21 to ↓ 47) the maximum recommended dose of Hydroxybupropion: bupropion should not be exceeded. AUC: ↔ No dose adjustment is necessary for Cmax: ↑ 50% (↑ 20 to ↑ 80) efavirenz. (CYP2B6 induction)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) paroxetine (HOS-086246) norepinephrine (HOS-090547) bupropion (HOS-086329) dopamine (HOS-085948) tenofovir disoproxil (HOS-108843) serotonin (HOS-085477) sertraline (HOS-086247) fluoxetine (HOS-085946)